|Post IPO Valuation|
|Venture Round, 12/2009 |
|Venture Round, 4/2010 ||$8.82M|
|Series C, 11/2011 |
ARCH Venture Partners
Third Rock Ventures
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops therapeutics in the field of cancer metabolism.
It also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The company’s therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases.
Agios Pharmaceuticals, Inc. was formerly known as CANCER METABOLISM THERAPEUTICS, INC. and changed its name to Agios Pharmaceuticals, Inc. in April 2008. The company is based in Cambridge, Massachusetts.